C-Met antisense oligodeoxynucleotide inhibits growth of glioma cells
- 30 June 2006
- journal article
- Published by Elsevier BV in Surgical Neurology
- Vol. 65 (6), 533-538
- https://doi.org/10.1016/j.surneu.2005.11.024
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladderBritish Journal of Cancer, 2005
- The SH2-domian-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreadingOncogene, 2005
- Effects of hepatocyte growth factor/scatter factor on the invasion of colorectal cancer cellsin vitroWorld Journal of Gastroenterology, 2005
- Genetic Basis of Cancer of the KidneyClinical Cancer Research, 2004
- Prostate Cancer and the Met Hepatocyte Growth Factor ReceptorAdvances in Cancer Research, 2004
- Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomasGynecologic Oncology, 2003
- Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinomaCancer, 1999
- Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusionJournal of Neurosurgery, 1998
- Tyrosine kinase receptor indistinguishable from the c-met proteinNature, 1989
- Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extractionAnalytical Biochemistry, 1987